Formulating the Cancer Treatments of Tomorrow

Unraveling the Untapped Potential of Immuno-Oncology Technology

Both the pace and varied methods by which medical clinicians utilize newer cancer treatments have been evolving exponentially for years now. For its part, Agilex Biolabs is proud to be able to make meaningful contributions to ongoing research and the promise of successful clinical trials.

Many of the cancer-fighting drugs of today are able to accomplish their intended purpose by binding to cell surface receptors. Others are able to modulate pathways as they take the form of small molecules; these drugs then infiltrate the cell and bind to their targets, thereby immobilizing or preventing phosphorylation.

Nowadays, the exponential benefits of using advanced technology in the field of immuno-oncology have become as apparent as they are numerous. Multiple newer techniques have proven to be invaluable allies in the effort to identify and target cancer cells, and Agilex is right there in the mix, breaking new ground.

Unmasking the Intricacies: From Cell Surface Receptors to Intracellular Targets

One of the focal points of a recent deep dive, courtesy of Agilex Labs, is the exploration of immuno-oncology drugs and their diverse mechanisms of action. Since some medicines bind to cell surface receptors while others permeate the cell and bind to targets within — effectively halting the phosphorylation process — a nuanced understanding is central to making continued progress.

Ongoing research and the advancement of allied technology go hand-in-hand toward unraveling the potential impact of these drugs on pathways vital to cancer treatment.

Phosphorylated Stat Proteins: A Key to Understanding Immuno-Oncology Pathways

Central to our downloadable white paper is the in-depth analysis of phosphorylated stat proteins within whole blood samples. In the context of an immuno-oncology program, where a drug targets specific pathways, inhibiting phosphorylation becomes a pivotal step.

This inhibition, in turn, suppresses the activation of downstream target genes. This intricate interplay between pathway activation and target gene regulation forms the cornerstone of the Agilex approach.

Droplet Digital PCR Tech: An Invaluable Tool for Quantitative Analysis

In our pursuit of precision, Agilex Biolabs employs state-of-the-art droplet digital PCR technology. This groundbreaking technique offers unparalleled quantitative insights, enabling us to discern a drug’s regulatory impact on target genes.

By deciphering these genetic alterations, Agilex researchers gain critical insights into cellular behavior, including proliferation, apoptosis resistance, and metastatic potential.

Toward a Tailored Technology Solution for Immuno-Oncology Pioneers

Agilex Biolabs research provides a comprehensive guide for those operating in the immuno-oncology space. The Agilex team is committed to providing invaluable resources for drug developers. By presenting a systematic approach to addressing crucial questions in a bioanalytical context, we equip research teams with the advanced tools they need to navigate the complexities of drug development and clinical trials.

The Agilex white paper complements formalized PK immunogenicity assays, providing a holistic understanding of drug efficacy. Together, these assays offer a comprehensive view of pathways influenced by the drug, paving the way for informed decisions in drug development.

Unlocking Potential Future Treatments

What sets Agilex Biolabs research apart is the depth of scientific capability that we bring to the table.

Agilex is committed to collaborating with sponsors to explore additional pathways using a similar scientific approach, exemplifying our dedication to advancing the field of immuno-oncology.

Unlock the Future of Immuno-Oncology

At Agilex Biolabs, we understand the critical importance of leveraging advanced techniques to propel drug development and clinical trials forward.

Our recently released white paper delves into the intricate world of flow cytometry, intracellular signal transduction pathways, and digital PCR, offering invaluable insights for those navigating the immuno-oncology space. To help speed drug development, researchers at AGX are providing information that will be of significant interest to anyone working in the field of immuno-oncology.

If your organization is currently devising its overall clinical trial strategy, the resource linked below will help provide solutions for addressing questions in a bioanalytical context. It may prove especially useful for companies looking to bring a clinical trial to Australia, but anyone working in the immuno-oncology space can benefit from these insights.

Embark on a transformative journey in immuno-oncology with Agilex Biolabs. Our white paper encapsulates the essence of our unwavering commitment to progress. If you’re working in the immuno-oncology space, we invite you to reach out to us. Let’s talk about how we can propel your drug development and clinical trial projects to new heights. Together, we can make a difference in the fight against cancer. Contact us today!

To learn more about conducting your drug development program in Australia or about Agilex Biolabs, contact our experts today.